研究单位：[1]Shanghai East Hospital[2]Beijing InnoCare Pharma Tech Co., Ltd.[3]The first affiliated hospital of bengbu medical college,Bengbu,Anhui,China,233000[4]Anhui Provincal Cancer Hospital,Hefei,Anhui,China,230031[5]Cancer Hospital.Chinese Academy of Medical Sciences,Beijing,Beijing,China,100021[6]Beijing Cancer Hospital,Beijing,Beijing,China,100142[7]Fujian Cancer Hospital,Fuzhou,Fujian,China,350014[8]The First Affiliated Hospital of Lanzhou University,Lanzhou,Gansu,China,730000[9]Affiliated Cancer Hospital and Institute of Guangzhou Medical University,Guangzhou,Guangdong,China,510000[10]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China,510000[11]The Second Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,50000[12]Harbin Medical University cancer hospital,Harbin,Heilongjiang,China,150081[13]Henan Provincial People's Hospital,Zhengzhou,Henan,China,450003[14]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450003[15]Henan Tumor Hospital,Zhengzhou,Henan,China,450008[16]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[17]Union Hospital Toji Medical College Huazhong University of Science and Technology,WuHan,Hubei,China,430000[18]Tongji Hospital Tongji Medical College of HUST,Wuhan,Hubei,China,430030[19]Xiangya Hospital Central South University,Changsha,Hunan,China,410008[20]Hunan Cancer Hospital,Changsha,Hunan,China,410013[21]Hunan Tumor Hospital,Changsha,Hunan,China,410013[22]Nantong Cancer Hospital,Nantong,Jiangsu,China,226361[23]Affiliated Hospital of Jiangnan University,Wuxi,Jiangsu,China,214122[24]The first hospital of jilin University,Changchun,Jilin,China,130000[25]Liaoning Cancer Hospital & Institute,Shenyang,Liaoning,China,110801[26]Shandong Provincial Institute of Cancer Prevention and Treatment,Jinan,Shandong,China,250000[27]QiLu Hospital of Shandong University,Jinan,Shandong,China,250012[28]Linyi Cancer Hospital,Linyi,Shandong,China,276000[29]Shanghai Ninth People's Hospital, Shanghai JiaoTong University School Medicine,Shanghai,Shanghai,China,20000[30]Zhongshan Hospital Affiliated to Fudan University,Shanghai,Shanghai,China,200032[31]Shanghai East Hospital,Shanghai,Shanghai,China,200135[32]The First Affiliated Hospital of Xi An Jiaotong University,Xi'an,Shanxi,China,710061[33]Sichuan Tumor Hospital,Chengdu,Sichuan,China,610000[34]West China Hospital, Sichuan University,Chengdu,Sichuan,China,610000[35]Second People's Hospital of Yibin City,Yibin,Sichuan,China,644000[36]Tianjin medical university cancer institute&hospital,Tianjin,Tianjin,China,300060[37]Shaoyifu Hospital of Zhejiang University Medical College,Hangzhou,Zhejiang,China,310000[38]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310000[39]Zhejiang Provincial People's Hospital,Hangzhou,Zhejiang,China,310014
研究目的：
This is a phase II clinical trial in treated patients with advanced solid tumors with FGF/FGFR gene alterations. The purpose of this study is to evaluate the efficacy and safety of ICP-192.
